论文部分内容阅读
目的:探讨卡培他滨联合奥沙利铂与贝伐珠单抗治疗不可切除的转移性结直肠癌的效果及对患者5年生存期的影响。方法:抽取2008年6至2014年6月驻马店市第一人民医院收治的114例不可切除的转移性结直肠癌患者为研究对象，按照随机数字表法分为研究组与对照组，每组57例。对照组应用卡培他滨联合奥沙利铂治疗，研究组在对照组基础上联合贝伐珠单抗治疗。治疗3个周期后，比较两组患者的治疗效果。比较治疗3个周期内两组患者药物严重不良反应的发生情况。比较两组患者1、3、5年生存率。结果:治疗期间，研究组脱组病例1例，对照组为2例。治疗3个周期后，研究组患者疾病控制率、总缓解率分别为91.07%(51/56)、80.36%(45/56)，高于对照组的70.91%(39/55)、61.82%(34/55)，n P0.05)。研究组1年生存率(80.85%，38/47)高于对照组(61.36%，27/44)，n P0.05)。n 结论:不可切除的转移性结直肠癌患者给予卡培他滨联合奥沙利铂联合贝伐珠单抗治疗，可有效提高临床疗效，保证用药安全性，并延长生存期。“,”Objective:To investigate efficacy of capecitabine combined with oxaliplation and bevacizumab on unresectable metastatic colorectal cancer, and influence on 5-year survival.Methods:A total of 114 patients with unresectable metastatic colorectal cancer in the First People’s Hospital of Zhumadian from June 2008 to June 2014 were selected as the research subjects, and they were divided into study group and control group according to the random number table method, with 57 cases in each group. Control group was treated with capecitabine combined with oxaliplatin, and the study group was treated with bevacizumab based on the treatment of control group. After 3 courses of treatment, the treatment effect was evaluated. The occurrence of serious adverse reactions were compared between the two groups during 3 courses of treatment. The 1-year, 3-year, and 5-year survival rates were compared between the two groups.Results:During the treatment, 1 case in the study group and 2 cases in control group were out of the group. After 3 courses of treatment, the disease control rate and total remission rate in study group were 91.07%(51/56) and 80.36%(45/56), higher than the 70.91%(39/55) and 61.82%(34/55) in control group (n P0.05). The 1-year survival rate of patients in study group (80.85%, 38/47) was higher than that in control group (61.36%, 27/44),n P0.05).n Conclusions:Capecitabine combined with oxaliplatin and bevacizumab for patients with unresectable metastatic colorectal cancer can effectively improve clinical efficacy, ensure drug safety, and prolong survival time.